Sector News

Aerpio may hang the ‘for sale’ sign up, axes CEO after eye drug flop

October 21, 2019
Life sciences

In a classic plot line for biotechs, Aerpio Pharmaceuticals is seeking a “strategic review” for its business and assets after being hit by a trial failure for its leading med earlier this year.

The micro-cap biotech, with a market cap worth less than $20 million and trading in penny stock territory, said its board is “exploring the potential for an acquisition, company sale, merger, business combination, asset sale, in-license, out-license or other strategic transaction.” The chief executive, Michael Rogers, is also out the door.

Aerpio added that it “does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved,” so don’t expect any more press releases until some sort of deal is done—or not, as the case may be.

As well as looking to potentially sell off some or all of the company, Aerpio’s already slimming down, or, as it puts it, “streamlin(ing) operations in order to preserve its capital and cash resources.” It had under $50 million at last count in June.

Joseph Gardner, Ph.D., its current president (and founding CEO of Akebia Therapeutics), will now lead the dwindling C-suite team as Rogers alongside Chief Financial Officer Stephen Hoffman “have transitioned from their roles,” the biotech said in a brief update.

Back in May, shares in Aerpio were more than halved after the failure of its leading drug candidate.

The midstage test, known as the TIME-2b study, was assessing its drug AKB-9778 in diabetic retinopathy but missed its primary endpoint of a two-step reduction in its diabetic retinopathy severity score score when pitted against a dummy treatment.

The percentage of patients achieving this endpoint for the injectable AKB-9778 twice daily and placebo were 9.6% and 3.8%, respectively (p=0.270). Across all eyes, those achieving this endpoint was 8.6% and 2.7%, for AKB-9778 BID and placebo, respectively (p=0.158). That was a hard fail, and one that sent its shares into a free fall from which it has not recovered.

By Ben Adams

Source: Fierce Biotech

Related News

February 20, 2020

Endo replaces CEO, appoints M&A specialist to board in possible push for deals

Life sciences

LinkedIn Twitter FacebookAfter three years at the helm of troubled drugmaker Endo, CEO Paul Campanelli shocked analysts in November with his announcement he would step away to the chairman role. […]

February 20, 2020

Gilead poaches Bristol-Myers oncology executive to lead research biology

Life sciences

LinkedIn Twitter FacebookGilead Sciences has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Johnson & Johnson and the Dana-Farber Cancer Institute, who joins from Bristol-Myers […]

February 19, 2020

How big data could revolutionise the healthcare industry

Life sciences

LinkedIn Twitter FacebookWe generate data about ourselves all the time, the acquisition and interpretation of which is big business. In many cases, this data may be fairly trivial or inconsequential. […]